Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daphne S. Bakker"'
Autor:
Judith L. Thijs, Eveline M. Delemarre, Jorien van der Schaft, Marjolein S. de Bruin-Weller, Edward F. Knol, Stefan Nierkens, Julia Drylewicz, Femke van Wijk, Barbara Giovannone, Daphne S. Bakker
Publikováno v:
Journal of Allergy and Clinical Immunology. 147:189-198
Background Atopic dermatitis (AD) is a highly heterogeneous disease, both clinically and biologically, whereas patients are still being treated according to a “one-size-fits-all” approach. Stratification of patients into biomarker-based endotypes
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients
Autor:
Cynthia C. A. van Amerongen, Marie L A Schuttelaar, Lieneke F.M. Ariëns, Tessa A. Kouwenhoven, Edward F. Knol, Evelien M Delemarre, Femke van Wijk, Deepak M.W. Balak, Julia Drylewicz, Judith L. Thijs, Marijke Kamsteeg, Jorien van der Schaft, Margreet L E Romeijn, Stefan Nierkens, Barbara Giovannone, Marjolein S. de Bruin-Weller, Daphne S. Bakker
Publikováno v:
Allergy, 75(1), 116-126. Wiley-Blackwell
Allergy, 75, 116-126
Allergy, 75, 1, pp. 116-126
Allergy, 75(1), 116. Wiley-Blackwell
Allergy, 75, 116-126
Allergy, 75, 1, pp. 116-126
Allergy, 75(1), 116. Wiley-Blackwell
INTRODUCTION: Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce.OBJECTIVE: To study the effect of 16-week treatment with dupilumab on c
Autor:
Marijke Kamsteeg, Lotte S. Spekhorst, Marjolein S. de Bruin-Weller, Jorien van der Schaft, Lieneke F.M. Ariëns, Daphne S. Bakker, Marie L A Schuttelaar, Judith L. Thijs, Inge Haeck, Annebeth E. Flinterman
Publikováno v:
Acta Dermato-Venereologica, 101
Acta dermato-venereologica, 101(10). ACTA DERMATO-VENEREOLOGICA
Acta Dermato-Venereologica, Vol 101, Iss 10 (2021)
Acta dermato-venereologica, 101(10). ACTA DERMATO-VENEREOLOGICA
Acta Dermato-Venereologica, Vol 101, Iss 10 (2021)
Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa497dbe6e193a5fa4c5f001f7686082
https://doi.org/10.2340/00015555-3886
https://doi.org/10.2340/00015555-3886
Autor:
Marie L A Schuttelaar, Lotte S. Spekhorst, Jorien van der Schaft, Angelique N Voorberg, Daphne S. Bakker, Inge Haeck, Lieneke F.M. Ariëns, Marjolein S. de Bruin-Weller, Tessa A. Kouwenhoven, Ilona de Ridder, Judith L. Thijs, A. J. Oosting, Annemieke Sloeserwij, Geertruida L E Romeijn, Marijke Kamsteeg
Publikováno v:
Journal of the American Academy of Dermatology, 84, 1000-1009
Journal of the American Academy of Dermatology, 84, 4, pp. 1000-1009
Journal of the American Academy of Dermatology, 84(4), e279-e280. MOSBY-ELSEVIER
Journal of the American Academy of Dermatology, 84, 4, pp. 1000-1009
Journal of the American Academy of Dermatology, 84(4), e279-e280. MOSBY-ELSEVIER
BackgroundReal-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.ObjectiveTo study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ce1d59f35814b82811f6ee35b7e200
http://hdl.handle.net/2066/233486
http://hdl.handle.net/2066/233486